This multicenter, open-label study is designed to assess the efficacy of adding levofloxacin (a new fluoroquinolone antibiotic) to the standard four drug anti-tuberculosis regimen in HIV infected patients. It will compare the short-term response between induction regimens as well as the rate of failure while on therapy and relapse after completion of therapy between intermittent continuation regimens of different durations.
NIH ExPorter
NIH ExPorter